One caveat: because several risk estimates reached higher confidence intervals, a clinically meaningful risk cannot be completely ruled out.
Here: 6 key beliefs patients hold about DMARDs that drive their reluctance to continue therapy.
Here’s a brief look at medications for rheumatologic disorders that were approved or granted a new indication in 2018.
This novel interleukin-23 inhibitor targets psoriatic inflammation.
In late-breaking clinical trials, 3 novel biologic drugs show promise for the treatment of moderate to severe plaque psoriasis.
However, the degree to which biosimilars will drive down the cost of biologic therapy remains to be seen.
Mepolizumab gets the nod for the rare disease formerly known as Churg-Strauss syndrome.
The aim of this study: to determine which patients need biologic therapy after starting methotrexate.
Sjogren’s fails a clinical trial with rituximab and a cost analysis. Even with a significant discount, it’s still not cost effective.